Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck

(2019) Emmanuel Seront et al.   Frontiers in Oncology

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer

(2019) Nicholas C. Turner et al.   JOURNAL OF CLINICAL ONCOLOGY

Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo

(2019) Yudi Xiong et al.   BIOMEDICINE & PHARMACOTHERAPY

Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib

(2019) Melania Poratti et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer

(2018) Hyun Joo Lee et al.   CANCER LETTERS

Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies

(2018) Alice Lee et al.   CANCER TREATMENT REVIEWS

Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non–Small Cell Lung CancerIn VitroandIn Vivo

(2018) Sarwat Naz et al.   CLINICAL CANCER RESEARCH

Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma

(2018) Xiaoyang Li et al.   Cell Death & Disease

CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer

(2018) Mangala Iyengar et al.   Oncotarget

Palbociclib-induced autophagy and senescence in gastric cancer cells

(2017) Claudio A. Valenzuela et al.   EXPERIMENTAL CELL RESEARCH

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

(2016) A. J. Walker et al.   CLINICAL CANCER RESEARCH

Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment

(2016) Guowei Gu et al.   CURRENT OPINION IN PHARMACOLOGY

Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?

(2016) Gaurav Agarwal et al.   WORLD JOURNAL OF SURGERY

Progress with palbociclib in breast cancer: latest evidence and clinical considerations

(2016) Andrea Rocca et al.   Therapeutic Advances in Medical Oncology

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

(2015) J. A. Beaver et al.   CLINICAL CANCER RESEARCH

Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?

(2015) Han Hsi Wong et al.   LANCET ONCOLOGY

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Targeting CDK4 and CDK6: From Discovery to Therapy

(2015) C. J. Sherr et al.   Cancer Discovery

Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo

(2014) Y.-X. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

(2013) J. Rader et al.   CLINICAL CANCER RESEARCH

Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition

(2012) Jeffry L. Dean et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

(2011) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer

(2011) Yoshimi Arima et al.   INTERNATIONAL JOURNAL OF CANCER

The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999–2004

(2008) Monica Brown et al.   CANCER